This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, J. I. Articles by Sosman, J. A. Search for Related Content PubMed PubMed Citation Articles by Clark, J. I. Articles by Sosman, J. A.

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon- in Patients with Advanced Renal Cell Carcinoma¹

Edward Hines, Jr., Veterans Affairs Hospital, Hines, Illinois 60141 [J. I. C., E. R. G., R. M., R. C. F., W. B. W., J. A. S.], and Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois 60153 [J. I. C., E. R. G., B. M., S. C. B., R. M., R. C. F., W. B. W., J. A. S.]

A limited institution Phase II pilot study was performed using a very low-dose combination of daily s.c. interleukin (IL)-2 with IFN--2b in patients with advanced renal cancer in an attempt to duplicate or increase the response documented with higher dose schedules without the attendant toxicity profile. We selected a dose of IL-2 with documented immunological activity and combined it with clinically active low-dose IFN. Between August 1994 and September 1996, 19 patients with metastatic renal cell carcinoma, who had been judged incapable of tolerating high-dose i.v. IL-2, were treated with IL-2 (1 million units/m²/day) and IFN (1 million units/day), administered s.c. daily. All treatments were administered on an outpatient basis. Virtually all patients had bulky tumor burden with multiple sites of involvement, including five patients with bone metastases. No major objective responses were observed; however, one patient experienced a minor response lasting 13 months, with an associated improvement in performance status. Median survival was 6 months, and 1-year survival was 16%. Toxicity was generally mild and consisted almost entirely of constitutional symptoms. No serious grade 3 or 4 toxicity was observed, although two patients withdrew from treatment due to treatment-related fatigue. On therapy, mild eosinophilia but no lymphocytosis was noted; in fact, peripheral lymphocyte counts decreased, only to rebound after treatment was discontinued. No toxic deaths occurred. Despite the reasonable tolerability of this daily low-dose s.c. regimen, we conclude that this regimen is an ineffective treatment in metastatic renal cell carcinoma patients who are incapable of tolerating high-dose i.v. IL-2.

This article has been cited by other articles:

				J. I. Clark, T. M. Kuzel, T. M. Lestingi, S. G. Fisher, P. Sorokin, B. Martone, M. Viola, and J. A. Sosman A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon {alpha}-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population Ann. Onc., April 1, 2002; 13(4): 606 - 613. [Abstract] [Full Text] [PDF]

				F. Recchia, S. De Filippis, M. Rosselli, G. Saggio, A. Cesta, L. Fumagalli, and S. Rea Phase 1B Study of Subcutaneously Administered Interleukin 2 in Combination with 13-cis Retinoic Acid as Maintenance Therapy in Advanced Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1251 - 1257. [Abstract] [Full Text]

				J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]

				V. Fachinger, T. Schlapp, W. Strube, N. Schmeer, and A. Saalmüller Poxvirus-Induced Immunostimulating Effects on Porcine Leukocytes J. Virol., September 1, 2000; 74(17): 7943 - 7951. [Abstract] [Full Text]